newsfilter
← Latest News
GlobeNewswire·

G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

- Achieved $46.3 Million in Net Revenue from Sales of COSELA® (trilaciclib) for Full Year 2023, Representing 48% Growth Over 2022; Provided 2024 Net COSELA Revenue Guidance of $60 to $70 Million - - Net COSELA